  The treatment of advanced non-small-cell lung cancer ( nsclc) has undergone a paradigm shift since the early 2000s. The identification of molecular subtypes of the disease , based on oncogenic drivers , has led to the development of personalized medicine and the ability to deliver molecularly targeted therapies to patients. In the 10 years that have elapsed since the discovery of the